Exogenous nitric oxide regulates activity and synthesis of vascular endothelial nitric oxide synthase

Background Nitric oxide (NO) – a major signalling molecule of the vascular system – is constitutively produced in endothelial cells (EC) by the endothelial NO synthase (eNOS). Since a reduced NO synthesis is an early sign of endothelial dysfunction and NO delivering drugs are used to substitute the impaired endothelial NO production, we addressed the effect of exogenous NO on eNOS in human umbilical venous endothelial cell cultures. Materials and methods The synthetic NO donor DETA/NO (trade name, but in the following we refer to detNO), that releases NO in a strictly first order reaction with a half life of 20 h, was used in our experiments. Results Short‐term (20–30 min) detNO treatment of EC increases the Ser¹¹⁷⁷ phosphorylation of the constitutively expressed endothelial NOS and the production of endogenous NO generated by eNOS from [³H]arginine. The phosphorylation of eNOS is Akt‐dependent and completely reverted by the phosphatidylinositol‐3 kinase (PI‐3K) inhibitor LY294002. A prolonged continuous exposure of EC to detNO 150 µmol L^?1 over a period of 24–48 h causes a reversible cell cycle arrest at G₁‐phase associated with a larger cell volume and increased cell protein content (hypertrophic phenotype of EC). The eNOS protein and mRNA of the hypertrophic cells and the generation of endogenous NO are reduced but eNOS phosphorylation could still be elevated by stimulation with vascular endothelial growth factor. Conclusions Our data explain clinical studies describing a short‐term but not a long‐term benefit of NO treatment for patients with cardiovascular risk factors. The results could be a rational approach to develop a generation of NO donors accomplishing a retarded release from NO donors that mimic the low continuous pulsatile stress‐induced release of endogenous NO.     

Fatty acid incorporation in endothelial cells and effects on endothelial nitric oxide synthase

BACKGROUND: The nature of fatty acids provided by the diet as well as plasma lipid metabolism can modify the composition and properties of plasma membrane and thus the activity of membrane proteins. In humans, as well as in experimental models, diabetes is associated with both an alteration in serum lipid profile and a documented endothelial dysfunction. This in vitro study investigated on an immortalized human endothelial cell line (EA.hy 926) the specific effects of several free fatty acids (FFAs) on the composition of cellular membranes and the regulation of endothelial nitric oxide synthase (eNOS). MATERIALS AND METHODS: 0.1% of lipid deprived serum was added to the incubation medium with 25 mM glucose in order to study the effects of individual fatty acids: myristic acid, palmitic acid, stearic acid, oleic acid or linoleic acid at 100 microM bound with albumin. The effects of the FFAs on the endothelial nitric oxide synthase were investigated on mRNA level by quantitative PCR, on protein level and Ser1177 phosphorylation by Western blot and on enzymatic activity on living cells using radiolabelled arginine. RESULTS: Free linoleic acid increased the membrane content in n-6 fatty acids (mainly C18: n-6 and its metabolites) with a decrease in saturated and monounsaturated fatty acids. These conditions decreased the basal eNOS activity and reduced the phosphorylation of eNOS-Ser1177 due to activation by histamine. Free palmitic acid enriched the membranes with 16 : 0 with a slight decrease in monounsaturated fatty acids. These conditions increased eNOS activation without increasing Ser1177 phosphorylation upon histamine activation. The addition of the other FFAs also resulted in modifications of membrane composition, which did not to affect eNOS-Ser1177 phosphorylation. CONCLUSION: Among the fatty acids used, only modification of the membrane composition due to linoleic acid supply disturbed the basal enzymatic activity and Ser1177 phosphorylation of eNOS in a way that limited the role of histamine activation. Linoleic acid might involve the dysfunction of both eNOS basal activity and its phosphorylation status and may then contribute to an impaired vasodilatation in vivo.     

辛伐他汀纳米粒通过调节诱导型一氧化氮合酶/内皮型一氧化氮合酶系统对小鼠脓毒症相关急性肺损伤的影响

目的探讨辛伐他汀纳米粒对脓毒症相关急性肺损伤小鼠肺组织中诱导型一氧化氮合酶（iNOS）/内皮型一氧化氮合酶（eNOS）平衡的调节以及对脓毒症小鼠预后的影响。 方法将90只C57 / BL6小鼠分为假手术组、脓毒症组、灌胃组、静脉制剂组及纳米粒组,每组各18只。采用盲肠结扎穿孔术（CLP）建立脓毒症小鼠模型;灌胃组小鼠通过灌胃针,给予辛伐他汀口服制剂灌胃治疗后进行CLP术;静脉制剂组及纳米粒制剂组小鼠CLP术后,立即分别通过尾静脉注射预配置好的辛伐他汀静脉制剂和辛伐他汀纳米粒制剂。其中每组12只小鼠用于7 d生存评估,另外6只用于24 h时间点标本采集。每24小时观察小鼠的生存情况,然后记算各组小鼠每日生存情况。采用苏木素-伊红（HE）染色观察5组小鼠病理变化并计算肺损伤病理评分,免疫组织化学法检测5组小鼠肺组织iNOS、eNOS表达水平。 结果Kaplan-Meier生存曲线结果显示,5组小鼠7 d生存情况比较,差异有统计学意义（χ² = 3.780,P < 0.001）。进一步两两比较发现,脓毒症组及灌胃组小鼠的7 d生存情况均较假手术组明显下降（P均< 0.001）,而纳米粒组小鼠的7 d生存情况显著优于脓毒症组（P = 0.001）。HE染色结果显示,假手术组小鼠肺组织未见明显病理征象;脓毒症组小鼠肺组织弥漫性中性粒细胞浸润、肺泡腔变小、肺泡间中隔增厚、肺间质弥漫性水肿、细胞排列紊乱、部分肺组织完整性遭破坏;灌胃组小鼠病理所示与脓毒症组相似;静脉制剂组及纳米粒组小鼠中性粒细胞渗出均较脓毒症组损伤减少、肺泡完整性较好、损伤程度较轻。5组小鼠肺损伤病理评分、iNOS及eNOS表达水平比较,差异均有统计学意义（F = 889.200、9.633、6.918,P均< 0.05）。进一步两两比较发现,脓毒症组小鼠的肺损伤病理评分、iNOS及eNOS表达水平与假手术组比较,差异均有统计学意义（P均< 0.05）;静脉制剂组及纳米粒组小鼠病理评分、iNOS及eNOS表达水平与脓毒症组比较,差异均有统计学意义（P均< 0.05）,且纳米粒组小鼠的肺损伤病理评分较静脉制剂组显著降低（P < 0.05）。 结论不同的辛伐他汀制剂具有不同的效应,其中纳米粒制剂对于脓毒症相关的肺损伤最具保护价值,建立eNOS与iNOS之间的平衡,可以成为具有保护效应的重要处理位点。     

Lack of association of endothelial nitric oxide synthase polymorphisms and migraine

Objective.— The aim of this study was to evaluate if 2 functional endothelial nitric oxide synthase (eNOS) gene polymorphisms might be risk factors for migraine.
Background.— Nitric oxide synthase promotes the synthesis of nitric oxide (NO). NO is a potent vasodilator and mediates several processes involved in migraine pathophysiology. Only one study has suggested an association with migraine with aura.
Methods.— We performed a sex- and age-matched case-control study using 2 eNOS polymorphisms (rs1800779 and rs1799983), which are in linkage disequilibrium. Genotypes were obtained with allele-specific probes in a real-time polymerase chain reaction assay. Genotypic and allelic distributions were compared with χ² method. We also estimated the reconstructed haplotypes and calculated ORs for individual haplotypes.
Results.— A total of 337 migraine patients (188 with aura) and 341 healthy controls were recruited. We found no significant differences in the distribution of genotypes and alleles for either polymorphism among clinical subgroups. Neither rs1800779 nor rs1799983 polymorphisms increased the risk for suffering from migraine aura.
Conclusions.— As others have previously reported, we failed to demonstrate genetic association of the eNOS gene with migraine.     

The peroxisome proliferator-activated receptor alpha agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung

In the present study, we have investigated the effect of the peroxisome proliferator-activated receptor α (PPARα) agonist fenofibrate on airway reactivity and the role of the endothelial nitric oxide synthase (eNOS)/NO pathway in this effect. Airway reactivity to methacholine was assessed in C57BL/6 mice treated or not with fenofibrate by whole-body plethysmography. In some experiments, animals were administered with the NOS inhibitor L-NAME, one hour before airway reactivity measurement. Expression and phosphorylation of eNOS were evaluated in lung homogenates from fenofibrate and control animals using Western blotting. Fenofibrate dose and time dependently decreased airway reactivity to methacholine in mice. A statistically significant (P < 0.05) reduction was observed after a treatment of 10 days with a dose of 3 or 15 mg/day fenofibrate. Mice treated with fenofibrate and administered with l-NAME exhibited similar reactivity to methacholine than vehicle-treated mice administered with the NOS inhibitor, suggesting that NO mediates fenofibrate-induced decrease in airway reactivity. eNOS levels remained unchanged in the lung from mice treated with fenofibrate, but phosphorylation of the enzyme at Ser-1177 was increased by 118% (P < 0.05). Taken together, our data demonstrate that fenofibrate downregulates airway reactivity to methacholine in the mouse and suggest that this effect could involve an increase in NO generation through an enhanced eNOS phosphorylation.     

大鼠创伤性脑水肿一氧化氮及其合成酶的变化

目的：探讨脑损伤后一氧化氮（ＮＯ）及一氧化氮合酶（ＮＯＳ）与脑水肿的关系。方法：建立大鼠创伤性脑水肿模型,按不同时间点处死动物,测定其脑含水量及静脉血ＮＯ 和脑组织中ＮＯＳ。结果：脑创伤后脑含水量随静脉血ＮＯ的增加而增加,组织ＮＯＳ则随ＮＯ 的增加而下降。结论：创伤性脑水肿与血ＮＯ 有密切相关性,组织中ＮＯＳ则是该过程的可能催化剂     

八肽缩胆囊素对脂多糖诱导血管内皮细胞诱生型一氧化氮合酶表达变化的抑制作用

目的探讨八肽缩胆囊素（CCK-8）对脂多糖（LPS）诱导血管内皮细胞诱生型一氧化氯合酶（iNOS）表达变化的影响。方法培养人脐静脉内皮细胞株ECV-304细胞。用0．01、0．1和1mg／L LPS处理2～24h，用生理盐水、10mol／LCCK-8和0．1mg／L LPS＋10^-8、10^-7、10^-8mol／L CCK-8处理16h；用比色法检测培养液中一氧化氮（NO）含量、细胞NOS活性，免疫细胞化学及蛋白质免疫印迹法检测iNOS蛋白表达。结果与生理盐水处理的对照组比较，LPS诱导培养液NO含量增多、细胞NOS活性增高、iNOS蛋白表达上调；CCK-8剂量依赣性抑制LPS的上述效应。而单独作用对iNOS蛋白表达、NOS活性和NO含量均无明显影响。结论CCK-8可以明显抑制LPS引起ECV-304细胞iNOS蛋白表达上调。减少NO生成。     

Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy

BACKGROUND: The efficacy of angiotensin-converting enzyme (ACE) inhibitors has been demonstrated in large clinical trials, but knowledge of the underlying mechanisms remains incomplete. Therefore, this study investigated the impact of ACE inhibitor therapy on cardiac nitric oxide (NO) synthases in patients with coronary artery disease (CAD) or heart failure. PATIENTS AND METHODS: The mRNA expression was quantified by standard calibrated competitive RT-PCR, protein expression by Western blotting and NOS activity by monitoring the conversion of [3H]arginine to [3H]citrulline during enzymatic formation of NO in tissue homogenates of myocardium of patients with, or without, ACE inhibitor treatment before elective coronary artery bypass grafting or heart transplantation. RESULTS: The mRNA expression (amol microg(-1) RNA) of endothelial NO synthase (eNOS) was higher (22.5 +/- 4.8, n = 23) in the atrial myocardium of patients taking ACE inhibitor treatment, before elective coronary artery bypass grafting, compared with patients not taking this therapy (8.9 +/- 0.7, n = 33, P < 0.0001). The ACE inhibitor therapy increased eNOS protein expression from [(9 +/- 0.7) relative units (RUs) to (12 +/- 0.9) RUs, P < 0.05, respectively] and cardiac NOS activity from 17.6 +/- 1.3 to 23.7 +/- 1.1 pmol mg protein(-1) min(-1) (P < 0.001, respectively). Inducible and neuronal NO synthase expression was not changed by the ACE inhibition. A similar up-regulation of eNOS by ACE inhibition was found in the left ventricles of patients with heart failure. The augmented endothelial NOS expression and activity was not the result of differences in clinical characteristics and concomitant therapy between the patient groups. CONCLUSION: Increased eNOS expression and activity might contribute to the beneficial effects of ACE inhibitor therapy in the treatment of CAD and heart failure.     

内皮型一氧化氮合酶基因转移对大鼠慢性低氧性肺动脉高压的预防作用

目的 探讨内皮型一氧化氮合酶(eNOS)基因转移对大鼠慢性低氧性肺动脉高压(CHPH)的预防作用.方法 雄性Wistar大鼠24只被随机分为常氧(N)组、低氧(H)组、低氧LacZ(H-LacZ)组和低氧eNOS(H-eNOS)组,每组6只.经气道转基因,H-eNOS组注入5×1012 pfu/L AdCMVceNOS 50μl,重复12次,H-LacZ组注入等量AdCMVLacZ,其他两组注入等量生理盐水;3 d后建立大鼠CHPH模型.低氧结束后(2周)检测血动力学指标[体循环平均动脉压(MSAP)、心率(HR)和平均肺动脉压(MPAP)],肺小血管肌化程度(肺小血管中肌型动脉所占比例)和右心室肥厚指数[右心室/(左心室+室间隔)],并行肺组织eNOS蛋白检测及环磷酸鸟苷(cGMP)和一氧化氮(NO)含量测定.结果 H-eNOS组大鼠MPAP、右心室肥厚指数和肺小血管肌化程度明显低于H组与H-LacZ组,明显高于N组(P均<0.01);各组大鼠HR和MSAP比较差异均无统计学意义(P均>0.05);H和H-LacZ组eNOS蛋白含量明显高于N组,低于H-eNOS组(P均<0.01);H组和H-LaeZ组大鼠肺组织NO含量明显低于N组,而H-eNOS组明显高于其他3组(P<0.05或P<0.01);N、H和H-LacZ组大鼠肺组织cGMP含量明显低于H-eNOS组(P均<0.01),且3组间比较差异无统计学意义(P均>0.05).结论 经气道eNOS基因转移,可增强肺组织eNOS活性,增加NO/cGMP含量,减少大鼠CHPH的发生率.     

内皮型一氧化氮合酶基因多态性与急性冠脉综合征患者尿酸的关系

目的 探讨中国汉族急性冠脉综合征(ACS)患者尿酸与内皮型一氧化氮合酶(eNOS)基因多态性的关系.方法 采用聚合酶链反应/限制性片段长度多态性方法分析58例ACS患者(ACS组)和43例对照组患者的eNOS基因Glu298→Asp变异体.结果 与对照组比较,ACS组eNOS基因Glu/Glu、Glu/Asp、Asp/Asp基因型频率差异无统计学意义(43.1%、36.2%、20.7%比48.8%、34.9%、16.3%,x2=0.446,P=0.800).与eNOS基因Glu298等位基因携带者比较,ACS的危险性在Asp/Asp携带者中并不增高[相对比值比(OR)1.34,95%可信区间(CI)0.479～3.755,P=0.575].eNOS基因Glu298→Asp变异体与Duke积分无显著性关系[Glu/Glu(48.33±19.61)分,Glu/Asp(38.19±15.12)分,Asp/Asp(46.73±19.90)分,P=0.248];但Glu298→Asp基因型与ACS组患者血清尿酸存在显著的关联[Glu/Glu(298.92±87.27)μmol/L,Glu/Asp(370.80±95.80)μmol/L,Asp/Asp(346.16±93.71)μmol/L,P=0.01 7].结论 在中国汉族人群中,eNOS基因Glu298→Asp多态性与ACS患者不相关,而与ACS组患者血清尿酸存在显著的关联.     

Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils

BACKGROUND: Prior use of aspirin in patients with acute coronary syndrome has been associated with a lower incidence of acute myocardial infarction. The aim of this study was to explore if prior aspirin therapy in unstable angina (UA) patients could modify systemic inflammatory markers such as interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha) and intercellular adhesion molecule-1 (ICAM-1) and the expression of endothelial nitric oxide synthase (eNOS) in neutrophils. MATERIALS AND METHODS: Unstable angina was defined as transient S-T segment changes without significant increases in CK and CK-MB. We studied 50 consecutive patients admitted to hospital within 24 h after the onset of chest pain. The number of patients with prior aspirin was significantly higher (n = 32) than those not taking aspirin (n = 18) on admission. RESULTS: Plasma levels of IL-6 and ICAM-1 were significantly increased in the UA patients when compared with the healthy control volunteers (n = 20) used as a reference for normal values. Plasma levels of both IL-6 and ICAM-1 were reduced in patients taking aspirin. There were no differences in the plasma levels of TNF-alpha between the UA patients and the control volunteers. The eNOS protein expression was also higher in neutrophils from the UA patients taking aspirin than in those not taking aspirin. CONCLUSION: Patients taking aspirin before UA showed a lower systemic inflammatory response and higher eNOS protein expression in their neutrophils     

肾血管性高血压对诱导型一氧化氮合酶表达及活性的影响

目的通过测定肾血管性高血压大鼠血管及肾组织诱导型一氧化氮合酶（iNOS）活性及表达的变化情况,探讨血压与iNOS间的关系。方法运用肾动脉不全结扎方法制备SD大鼠肾血管性高血压模型,并应用Greiss反应、L-精氨酸同位素标记法及Westernblot等分别测定一氧化氮的终产物——尿中NO     

雾化吸入氯胺酮对哮喘大鼠肺组织一氧化氮及一氧化氮合酶的影响

目的通过建立大鼠支气管哮喘模型,观察不同浓度氯胺酮对哮喘大鼠肺组织iNOS活性及NO含量的影响。方法SD大鼠随机分成对照组(N组)、哮喘模型组(A组)、不同浓度氯胺酮预处理组(分别为K1组、K2组)和地塞米松组(D组),每组8只。A组大鼠用卵白蛋白辅以百日咳杆菌菌苗和氢氧化铝为佐剂注射致敏,2周后雾化吸入卵蛋白激发哮喘;氯胺酮处理组大鼠用同样方法致敏,但在激发前分别给予雾化吸入氯胺酮25 g/L(K1组)和50 g/L(K2组);D组在激发前给予雾化吸入0.01%地塞米松;N组用生理盐水替代卵蛋白进行注射和吸入。每组分别测定其肺组织NO2-/NO3-水平、肺组织诱导型NOS(iNOS)和原生型NOS(cNOS)活性水平,并用免疫组织化学法观察iNOS在大鼠哮喘模型肺组织中的分布。结果A组肺组织中NO2-/NO3-和iNOS水平升高,iNOS和肺组织NO2-/NO3-水平呈高度正相关;K1、K2组肺组织中NO2-/NO3-和iNOS水平低于A组(P<0.05);D组肺组织中NO2-/NO3-和iNOS水平亦低于A组(P<0.05)。结论25 g/L或50 g/L的氯胺酮雾化吸入可抑制哮喘大鼠肺组织iNOS活性,降低NO含量,减轻大鼠肺部炎症。     

Expression of nitric oxide synthase in ulcerative colitis

Abstract. Nitric oxide (NO) is generated from L-arginine by a family of enzymes called the NO synthases. Previous investigators have proposed that the expression of this inducible enzyme (iNOS) may account for the characteristic vasodilatation, oedema and impairment of gut motility seen in active ulcerative colitis. Using a specific antibody to iNOS, we have investigated the distribution of this enzyme in colonic tissue from patients with histologically proven ulcerative colitis. Eight patients with ulcerative colitis expressed calcium-independent citrulline activity (9.96±2.34 pmol citrulline mg^-1 protein min^-1) and showed immunoreactivity to the iNOS antibody within the inflammatory infiltrate of the lamina propria, and also within the cytoplasm of the epithelial cells lining the colon. Five age-matched controls showed no calcium-independent citrulline activity (0.2 ±0.08 pmol citrulline mg^-1 protein min^-1) and no immunoreaction to the antibody. We conclude that this enzyme is present in colonic tissue including the epithelium from patients with active colitis. Inhibition of this enzyme may provide a novel therapeutic option for patients with active ulcerative colitis.     

NOS及NO在介导Aβ神经毒性和阿尔茨海默病发病机制中的作用

目的观察诱导型一氧化氮合酶(iNOS)抑制剂胍氨酸(AG)及神经元型一氧化氮合酶(nNOS)抑制剂7-硝基吲哚(7-NI)对β淀粉样蛋白1-40(Aβ1-40)在体神经毒性的干预,进一步探讨一氧化氮合酶(NOS)及一氧化氮(NO)在Aβ神经毒性和Alzheimer病(AD)发病机制中的介导作用。方法雄性SD大鼠35只,随机分为正常对照,生理盐水注射,Aβ1-40注射,AG+Aβ1-40,7-NI+Aβ1-40,花生油(Peanutoil,PO)+Aβ1-40、生理盐水+Aβ1-40共7组,每组5只。观察各组大鼠的Y迷宫学习记忆作业及局部神经元损伤情况。结果Aβ1-40海马组大鼠Y迷宫作业的获得和再现尝试次数均显著增加,分别是(27.8±2.3)和(19.7±4.7)次,与前两组比较有显著性意义(F获得=146.438,P获得=0.000;F再现=113.654,P再现=0.000)。海马齿状回颗粒细胞背侧带受损长度为(1.93±0.26)mm,局部胶质细胞反应明显。AG可逆转Aβ1-40导致的学习记忆和神经元损伤,其获得和再现尝试次数分别为(14.6±4.9)次和(8.5±2.1)次,与Aβ1-40注射组比较明显减少(F获得=146.438,P获得=0.000;F再现=113.654,P再现=0.000)。细胞带受损长度为(0.41±0.21)mm,胶质细胞反应减轻。7-NI则无干预作用。结论iNOS/NO参与了在体条件下对Aβ神经毒性的介导,在AD发病机制中具有重要作用。     

诱导型一氧化氮合酶与血管内皮生长因子C在宫颈癌中表达及其与淋巴结转移的相关性研究

目的探讨诱导型一氧化氮合酶（inducible nitric oxide synthase,iNOS）与血管内皮生长因子（vascularendothelial growth factor,VEGF）-C在宫颈癌组织中的表达及其与淋巴结转移之间的关系。方法 55例宫颈癌组织（宫颈癌组）与10例正常宫颈组织（对照组）,采用免疫组织化学SP法检测2组iNOS和VEGF-C的表达情况。结果宫颈癌组iNOS与VEGF-C阳性率分别为69.09%和63.64%,对照组分别为20.00%和10.00%,差异有统计学意义（P〈0.05）;iNOS表达与VEGF-C呈正相关（r=0.78,P〈0.01）;宫颈癌组iNOS（＋）VEGF-C（＋）者淋巴转移的发生率（54.55%）明显高于iNOS（-）VEGF-C（-）者（27.27%）（P〈0.05）。结论 iNOS、VEGF-C与宫颈癌的淋巴转移关系密切;针对iNOS、VEGF-C的靶向治疗可能成为宫颈癌治疗的新靶点。     

诱导型一氧化氮合酶与血管内皮生长因子C在宫颈癌中表达及其与淋巴结转移的相关性研究

目的探讨诱导型一氧化氮合酶(inducible nitric oxide synthase,iNOS)与血管内皮生长因子(vascularendothelial growth factor,VEGF)-C在宫颈癌组织中的表达及其与淋巴结转移之间的关系。方法 55例宫颈癌组织(宫颈癌组)与10例正常宫颈组织(对照组),采用免疫组织化学SP法检测2组iNOS和VEGF-C的表达情况。结果宫颈癌组iNOS与VEGF-C阳性率分别为69.09%和63.64%,对照组分别为20.00%和10.00%,差异有统计学意义(P<0.05);iNOS表达与VEGF-C呈正相关(r=0.78,P<0.01);宫颈癌组iNOS(+)VEGF-C(+)者淋巴转移的发生率(54.55%)明显高于iNOS(-)VEGF-C(-)者(27.27%)(P<0.05)。结论 iNOS、VEGF-C与宫颈癌的淋巴转移关系密切;针对iNOS、VEGF-C的靶向治疗可能成为宫颈癌治疗的新靶点。     

内皮一氧化氮合酶基因多态性与糖尿病肾病关系的研究

目的 探讨内皮一氧化氮合酶(eNOS)基因内含子4的多态性与糖尿病肾病的关系,以及其在中国人、马来西亚人和印度人中的分布。方法 选择258例病程在10年以上的2型糖尿病患者作为观察对象,其中中国人150例、马来西亚人71例、印度人37例。从患者全血中提取DNA,然后,进行聚酶链反应(PCR)、克隆及测序。结果 以往认为该基因有2种等位基因(a和b),而本研究发现3种等位基因,并对第3种多态(等位基因c)基因进行了序列分析;统计分析显示,等位基因a、b和c均与糖尿病肾病无显著相关性。结论 eNOS基因内含子4上的多态性有3种等位基因;该基因多态性与糖尿病肾病无显著相关性。     

冠脉内支架植入术对急性心肌梗死后血清内皮型一氧化氮合酶含量的影响

目的观察冠状动脉内支架植入术(PCI)对急性心肌梗死(AMI)后患者血清内皮型一氧化氮合酶(eNOS)含量的影响。方法将AMI患者分为PCI治疗组和非PCI治疗组,采用酶联免疫法测定AMI后治疗前、PCI术后3d、1、2、4、6、8周时血清eNOS的含量。非PCI治疗组在对应时间点抽血。比较两组患者不同病期血清一氧化氮合酶含量的变化。结果PCI治疗组3d即可见eNOS表达升高,4周时达高峰,非PCI治疗组仅于4周有少量表达(3d时OD值为,6.587±0.216对应3.458±0.212;4周时OD值为,7.198±0.211对应3.680±0.211)两组差异有统计学意义(P0.01)。二者均于6周开始下降。结论AMI后早期PCI治疗可促进患者血清eNOS表达升高,通过提高缺血心肌内一氧化氮的含量,起到减轻缺血区心肌组织的损伤,改善心肌供血。     

吸烟者内皮型一氧化氮合酶基因G894T多态性与冠心病的相关性研究

目的探讨吸烟者内皮型一氧化氮合酶基因（eNOS）G894T多态性与冠状动脉粥样硬化性心脏病（冠心病）的发生及其严重程度间的关系。方法将203例吸烟者和182例非吸烟者根据冠状动脉造影结果分为冠心病组（196例）和对照组（189例）,以冠状动脉病变支数判定严重程度。以聚合酶链式反应-限制性片段长度多态性（PCR—RFIP）检测eNOS基因G894T多态性,按吸烟与否分析G894T多态性与冠心病的关系。结果冠心病组GT＋TT基因型分布与T基因突变频数明显高于对照组（x^2=4．26、6．21,P均〈0．05）;吸烟者基因GT＋TT型及T等位基因频率均显著高于非吸烟者（x^2〈5．82、5．77,P均〈0．05）;冠心病组eNOS基因型分布在单支与多支病变组之间差异无统计学意义（x^2=3．36,P〉0．05）,而吸烟的冠心病患者差异有统计学意义（x^2=6.48,P〈0．05）,吸烟的GG＋TT型者更可能发生多支病变,OR=3．42,95％CI（1．440—4.400）。结论eNOS894位点G→T、吸烟与冠心病的发生及其严重程度间的关系密切。